|
|
帕博利珠单抗治疗转移性恶性黑色素瘤的1例病例报告
|
Abstract:
恶性肿瘤的免疫靶向治疗是近年来临床肿瘤学的重大进展。细胞程序性死亡受体(programmed death receptor 1, PD-1)/程序性死亡配体(programmed death ligand 1, PD-L 1)信号通路阻断剂治疗恶性黑色素瘤取得了良好的效果。我们应用在一例中我国新上市的PD-1抑制剂帕博利珠单抗治疗转移性黑色素瘤，取得了显著疗效。
Immune targeted therapy of malignant tumor is a major progress of clinical oncology in recent years. Programmed cell death receptor (programmed death receptor 1, PD-1)/apoptosis ligand (programmed death ligand 1, PD-L1) signaling pathway blockers treatment of malignant melanoma achieved good results. We applied in China’s newly listed PD-1 inhibitor pembrolizumab in the treatment of a patient with metastatic malignant melanoma pulmonary metastasis, and achieved good result, as reported below.
| [1] | Herbst, R.S., Baas, P., Kim, D.W, et al. (2015) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Ad-vanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomized Controlled Trial. The Lancet, 387, 1540-1550. |
| [2] | Couzin-Frankel, G. (2013) Cancer Immunotherapy. Science, 342, 1432-1433. https://doi.org/10.1126/science.342.6165.1432 |
| [3] | 李艺柔, 吴思, 赵静. 癌症免疫疗法研究概述[J]. 生物学教学, 2019, 44(5): 3-5. |
| [4] | 杨长良, 张爽, 柳菁菁, 等. 新型免疫检查点——恶性肿瘤免疫治疗研究进展[J]. 肿瘤防治研究, 2018, 45(12): 1027-1035. |
| [5] | Hellmann, M.D., Ciuleanu, T.E., Pluzanski, A., et al. (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. The New England Journal of Medicine, 378, 2093-2104.
https://doi.org/10.1056/NEJMoa1801946 |
| [6] | Kim, E.S., et al. (2018) Primary Efficacy Results from B-FIRST, a Prospective Phase II Trial Evaluating Blood-Based Tumor Mutational Burden (bTMB) as a Predictive Biomarker for Atezolizumab (atezo) in 1 L Non-Small-Cell Lung Cancer (NSCLC). ESMO 2018 Congress, 22 October 2018, 63-65. |
